Marksans Pharma Limited has informed the Exchange about General Updates regarding the Nomination and Remuneration Committee (the designated Compensation Committee) of the Company has, today i.e., September 24, 2025, approved grant of 4,00,000 (Four Lakh) Stock Options to the certain eligible employees of the Company and its subsidiaries under Marksans Employees Stock Option Scheme 2024.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's Nomination and Remuneration Committee approved the grant of 4,00,000 (Four Lakh) stock options to certain eligible employees of the company and its subsidiaries on September 24, 2025, under the Marksans Employees Stock Option Scheme 2024. The exercise price is fixed at Rs. 10 per option (face value of Re. 1 per equity share), with a vesting period of 1 year and an exercise window of 2 years from the date of grant. The scheme complies with SEBI's Share Based Employee Benefits and Sweat Equity Regulations, 2021, and has received shareholder approval and in-principle nods from BSE and NSE. No options have been vested, exercised, or lapsed yet.
This is a routine ESOP grant that will result in mild equity dilution (4 lakh shares) once exercised, and is generally seen as neutral to mildly positive since it aligns employee interests with shareholders. The Rs. 10 exercise price may offer meaningful value to employees depending on the current market price, but no direct material impact on short-term stock price is expected.